|
Groups |
Treatment |
Onset time in seconds |
| Pentylenetetrazole (PTZ) |
| Action |
Jerky movements |
Convulsion |
| I |
10% w/v DMSO
(5 ml/kg, i.p) Solvent Control |
101.37 ± 3.29 |
142.38 ± 4.67 |
170.27 ± 5.76 |
| II |
Gabapentin (2.5 mg/kg, i.p)
Positive Control |
212.90 ± 3.46 |
225.37 ± 3.57 |
255.67 ± 7.81 |
| III |
A-350619 (100 µM/ kg, i.p)
sGC activator |
96.02 ± 2.19 |
117.56 ± 1.78 |
140.32 ± 5.29 |
| IV |
Methylene blue (50 mg/kg, i.p)
sGC inhibitor |
171.29 ± 5.30 |
218.52 ± 6.78 |
260.39 ± 7.30 |
| V |
BRL 50481 (2 mg/kg, i.p)
PDE-7 inhibitor |
62.12 ± 4.27 |
80.38 ± 4.67 |
96.27 ± 5.06 |
| VI |
A-350619 (100 µM/ kg,i.p)
+ BRL 50481 (2 mg/kg, i.p) |
89.02 ± 4.09ΔΔΔ,ΨΨΨ |
103.36 ± 3.98 ΔΔΔ,Ψ |
118.22 ± 7.25 ΔΔΔ |
| VII |
Methylene blue (50 mg/kg, i.p) + BRL 50481 (2 mg/kg, i.p) |
158.29 ± 5.30***,ΨΨΨ |
187.35 ± 5.13***, ΔΔΔ,ΨΨΨ |
230.49 ± 9.74***,ΨΨΨ |
Data represented as mean ± SEM (n=6), which represents onset time of various phases of convulsion in seconds. Treatments were given 30 mins prior to chemical -convulsant injection of PTZ (60 mg/kg, i.p). *** denotes p<0.001 compared with A-350619 received group, ΔΔΔ denotes p<0.001 compared with methylene blue received group, Ψ and ΨΨΨ denotes p<0.01 and p<0.001, respectively, compared with BRL50481 received group (One-way ANOVA followed by Tukey-Kramer multiple comparisons test). |
